This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases evaluated odevixibat for treating Alagille syndrome, a rare disease primarily affecting liver function that can cause bile acid buildup in the liver and blood. This buildup often leads to intense itching (pruritus) that significantly reduces quality of life for patients. While Alagille syndrome typically begins in childhood and varies in severity, previous treatment options for pruritus have been limited and ineffective for many patients. Odevixibat works by helping remove bile acids through stool, thereby reducing pruritus symptoms and lowering blood bile acid levels in people with this condition.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial’ and was published in The Lancet Gastroenterology & Hepatology.

Visit The Lancet using the link to read the original article.